Does HPV type 16 or 18 prevalence in cervical intraepithelial neoplasia grade 3 lesions vary by age? An important issue for postvaccination surveillance

Future Microbiology

Volumn 7, Issue 2, 2012, Pages 193-199

  Brotherton, Julia M L ^a,b   Tabrizi, Sepehr N ^a,c,d   Garland, Suzanne M ^a,c,d,e  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^e ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

age; cervical intraepithelial neoplasia; HPV; HPV DNA; surveillance; vaccination

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CANCER GRADING; CANCER SCREENING; COMPARATIVE STUDY; DISEASE ASSOCIATION; FEMALE; HEALTH SURVEY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MAJOR CLINICAL STUDY; MASS SCREENING; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; SEROPREVALENCE; TREATMENT OUTCOME; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VACCINATION; VIRUS DETECTION; VIRUS TYPING;

ADOLESCENT; ADULT; AGE FACTORS; AUSTRALIA; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; GENOTYPE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; IMMUNIZATION PROGRAMS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; POPULATION SURVEILLANCE; PREVALENCE; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC; VACCINATION; YOUNG ADULT;

HUMAN PAPILLOMAVIRUS;

EID: 84856828375     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.11.161     Document Type: Article

References (41)

1. Clifford G, Smith J, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: A meta-analysis. Br. J. Cancer 89, 101-105 (2003). (Pubitemid 36897943)
2. Clifford G, Rana R, Franceschi S, Smith J, Gough G, Pimenta J. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol. Biomarkers Prev. 14, 1157-1164 (2005). (Pubitemid 40656461)
3. Smith JS, Lindsay L, Hoots B et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int. J. Cancer 121, 621-632 (2007). (Pubitemid 46986496)
4. Brestovac B, Harnett G, Smith D, Frost F, Shellam G. Human papillomavirus genotypes and their association with cervical neoplasia in a cohort of western Australian women. J. Med. Virol. 76, 106-110 (2005). (Pubitemid 40446463)
5. Stevens M, Tabrizi S, Quinn M, Garland S. Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial neoplasia or cervical cancer in Melbourne, Australia. Int. J. Cancer 16, 1017-1024 (2006). (Pubitemid 43886720)
6. Stevens MP, Garland SM, Tan JH, Quinn MA, Petersen RW, Tabrizi SN. HPV genotype prevalence in women with abnormal Pap smears in Melbourne, Australia. J. Med. Virol. 81, 1283-1291 (2009).
7. Castle, PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia grade 2. Obstet. Gynecol. Surv. 64, 306-308 (2009).
8. Franceschi S, Clifford G. Re: A study of the impact of adding HPV types to cervical cancer screening and triage tests [letter]. J. Natl Cancer Inst. 97(12), 938-939 (2005).
9. Wentzensen N, Schiffman M, Dunn ST et al. Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1700 women referred to colposcopy in Oklahoma. Int. J. Cancer 124, 964-969 (2009).
10. De Vuyst H, Clifford G, Li N, Franceschi S. HPV infection in Europe. Eur. J. Cancer 45, 2632-2639 (2009).
11. Sargent A, Bailey A, Almonte M et al. Prevalence of type-specific HPV infection by age and grade of cervical cytology. data from the ARTISTIC trial. Br. J. Cancer 98, 1704-1709 (2008). (Pubitemid 351684674)
12. Rodriguez AC, Schiffman M, Herrero R et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J. Natl Cancer Inst. 100, 513-517 (2008).
13. Wheeler CM, Hunt WC, Joste NE et al. Human papillomavirus genotype distributions. implications for vaccination and cancer screening in the United States. J. Natl Cancer Inst. 101, 475-487 (2009).
14. Chen W, Zhang X, Molijn A et al. Human papillomavirus type-distribution in cervical cancer in China: The importance of HPV 16 and 18. Cancer Causes Control 20, 1705-1713 (2009).
15. Sigurdsson K, Taddeo FJ, Benediktsdottir KR et al. HPV genotypes in CIN2-3 lesions and cervical cancer: A population based study. Int. J. Cancer 121, 2682-2687 (2007). (Pubitemid 350136412)
16. Stevens MP, Garland SM, Rudland E, Tan J, Quinn MA, Tabrizi SN. Comparison of the Digene Hybrid Capture 2 assay and Roche Amplicor and linear array human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal pap smear results. J. Clin. Microbiol. 45(7), 2130-2137 (2007). (Pubitemid 47203782)
17. Cuschieri KS, Cubie HA, Whitley MW et al. Multiple high-risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J. Clin. Pathol. 57, 68-72 (2004). (Pubitemid 38091314)
18. Kjaer SK, Breugelmans G, Munk C, Junge J, Watson M, Iftner T. Population-based prevalence, type and age-specific distribution of HPV in women before introduction of an HPV vaccination program in Denmark. Int. J. Cancer 123, 1864-1870 (2008).
19. Howell-Jones R, Bailey A, Beddows S et al. Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England. Br. J. Cancer 103, 209-216 (2010).
20. Castle PE, Schiffman M, Wheeler CE, Wentzensen N, Gravitt PE. Human papillomavirus genotypes in cervical intraepithelial neoplasia. Cancer Epidemiol. Biomarkers. Prev. 19, 1675-1681 (2010).
21. Masumoto N, Fujii T, Ishikawa M et al. Dominant human papillomavirus 16 infection in cervical neoplasia in young Japanese women: study of 881 outpatients. Gynecol. Oncol. 94(2), 509-514 (2004). (Pubitemid 39024561)
22. Carozzi FM, Tornesello ML, Burroni E et al. HPV Prevalence Italian Working Group. Prevalence of human papillomavirus types in high-grade cervical intraepithelial neoplasia and cancer in Italy. Cancer Epidemiol. Biomarkers Prev. 19(9), 2389-2400 (2010).
23. Castle PE, Shaber R, LaMere BJ et al. Human papillomavirus (HPV) genotypes in women with cervical precancer and cancer at Kaiser Permanente Northern California. Cancer Epidemiol. Biomarkers Prev. 20(5), 946-953 (2011).
24. Gargano JW, Nisenbaum R, Lee DR et al. Age-group differences in human papillomavirus types and cofactors for cervical intraepithelial neoplasia 3 among women referred to colposcopy. Cancer Epidemiol. Biomarkers Prev. doi:10.1158/1055- 9965 (2011) (Epub ahead of print).
25. Baandrup L, Munk C, Andersen KK, Junge J, Iftner T, Kjr SK. HPV16 is associated with younger age in women with cervical intraepithelial neoplasia grade 2 and 3. Gynecol. Oncol. doi:10.1016/j. ygyno.2011.10.020 (2011) (Epub ahead of print).
26. Porras C, Rodriguez AC, Hildesheim A et al. Human papillomavirus types by age in cervical cancer precursors: Predominance of human papillomavirus 16 in young women. Cancer Epidemiol. Biomarkers Prev. 18(3), 863-865 (2009).
27. Ivansson EL, Gustavsson IM, Wilander E, Magnusson PKE, Gyllensten UB. Temporal trends over 3 decades and intrafamilial clustering of HPV types in Swedish patients with cervical cancer in situ. Int. J. Cancer 125, 2930-2935 (2009).
28. Evans MF, Adamson CS, Papillo JL, St John TL, Leiman G, Cooper K. Distribution of human papillomavirus types in Thin Prep Papanicolau tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes. Cancer 106, 1054-1064 (2006).
29. Chao A, Jao MS, Huang CC et al. Human papillomavirus genotype in cervical intraepithelial neoplasia grade 2 and 3 of Taiwanese women. Int. J. Cancer 128(3), 653-659 (2010).
30. Onuki M, Onuki M, Matsumoto K et al. Human papillomavirus infections among Japanese women. Age-related prevalence and type-specific risk for cervical cancer. Cancer Sci. 100, 1312-1316 (2009).
31. Sukasem C, Pairoj W, Saekang N et al. Molecular epidemiology of human papillomavirus genotype in women with high-grade squamous intraepithelial lesion and cervical cancer: will a quadrivalent vaccine be necessary in Thailand? J. Med. Virol. 83(1), 119-126 (2011).
32. Garland SM, Brotherton JML, Condon JR et al. Human papillomavirus prevalence amongst indigenous and non-indigenous Australian women prior to a national HPV vaccination program. BMC Med. 9(1), 104 (2011).
33. Khan MJ, Castle PE, Lorincz AT et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl Cancer Inst. 97(14), 1072-1079 (2005). (Pubitemid 41417924)
34. Kjlr SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: Role of persistence. J. Natl Cancer Inst. 102(19), 1478-1488 (2010).
35. Brotherton JML. How much cervical cancer in Australia is vaccine preventable? A meta-analysis. Vaccine 26, 250-256 (2008). (Pubitemid 50009654)
36. Lehtinen M, Paavonen J, Wheeler CM et al. for the HPV PATRICIA Study Group. Overall efficacy of HPV-16/18 AS04- adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. doi:10.1016/S1470- 2045(11)70286-8 (2011) (Epub ahead of print).
37. Mu oz N, Kjaer SK, Sigurdsson K et al. Impact of human papillomavirus (HPV)- 6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J. Natl Cancer Inst. 102(5), 325-339 (2010).
38. Stoler M. It is more complicated than you think: doctor, which HPV type caused that lesion? HPV Today, 4-6 February (2010).
39. Quint W, Jenkins D, Molijn A et al. One virus one lesion - individual components of CIN lesions contain a specific HPV type. J. Pathol. 30. doi:10.1002/path.3970 (2011) (Epub ahead of print).
40. Espina V, Heiby M, Pierobon M, Liotta LA. Laser capture microdissection technology. Expert Rev. Mol. Diagn. 7(5), 647-657 (2007). (Pubitemid 47547729)
41. Paavonen J, Naud P, Salmeron J et al. Efficacy of human papillomavirus (HPV)- 16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374, 301-314 (2009).